- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01659242
Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis:an Ultrasound/Magnetic Resonance Imaging Study
Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis Patients With Active Disease Despite Methotrexate: an Ultrasound and Magnetic Resonance Imaging Study
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Singapore, Singapore, 169608
- Singapore General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Male and female patients aged between 21 and 65 years.
- Patients with no childbearing potential (For example postmenopausal or sterilised) or have decided not to have offspring(s).
- All female patients must consent not to get pregnant/breastfeed, male patients must consent not to father a child and all must consent to practice effective birth control.
- Fulfills either the 1987 ACR criteria and/or the 2010 ACR / EULAR RA Classification Criteria.
- Seropositivity: Rheumatoid factor (RF) and/or anti -cyclic citrullinated protein antibodies (anti-CCP) must be positive.
- MCPJ(s) and/or Wrist(s) joint(s) involvement.
- Rheumatoid arthritis patients (less than 5 years duration) who remain at least moderately active based on DAS28 score of > 3.2, following 3 months of therapy with an optimal dose of methotrexate(e.g. at least 15 mg/week).
- If patient is on oral corticosteroids, this should not exceeding 10mg prednisolone daily (or oral steroid equivalent) for at least 4 weeks and should be at an unchanged dose for at least 2 weeks before entering study.
- If patient is on NSAIDs, this should be at an unchanged dose for at least 2 weeks before entering study.
- Glomerular filtration rate > 60 mls/min/1.73m2.
Exclusion Criteria
Patient known to have the following medical condition(s) will be excluded:
- Other autoimmune disease /inflammatory joint disease/connective tissue disease ( e.g. lupus, seronegative spondylarthropathy (e.g. ankylosing spondylitis/psoriatic arthropathy ), reactive arthritis, overlap syndrome, primary sjogren syndrome and mixed connective tissue disease.)
- Inflammatory arthritis with onset before 18 years old.
- Current or previous history of cancer or lymphoproliferative disease.
- HIV positive status, Hepatitis B/C positive status.
- Persistent and/or severe infection in the previous 12 weeks.
- Major traumatic injury, terminal illness, or other medical condition(s)that could place the patient at risk to participate in the study.
- Clinically relevant cardiovascular (e.g unstable ischemic heart disease), neurological (e.g recent stroke), gastroenterology (e.g active peptic ulcer disease), renal (e.g chronic renal failure), hepatic (e.g alcoholic liver disease, fatty liver) and any other major systemic disease that could i) place the patient at risk to participate in the study; or ii) make protocol implementation difficult; or iii) make study results interpretation difficult.
- Presence of any known condition(s)/circumstance(s) which would negatively impact compliance or study completion.
Impaired laboratory parameters:
- Hemoglobin less than 10.5 g/dl, white blood count less than 4 x 10 (9)/L , platelet count less than 150 x 10(9)/L.
- Deranged Liver function test: e.g. elevated AST/ALT.
- Wants to consume alcohol while taking the study medications.
- Body weight that is less than 45 kg.
- Pregnancy/Breastfeeding/Male patient wishing to father children.
Patients with the following medication history will be excluded:
- History of Glucose 6 Phosphate Dehydrogenase (G6PD) deficiency.
- Known allergy to: i) study medications; or ii) contrast; or iii) drugs whose chemical structures are similar (e.g. sulphonamides, salicylates, etc).
- On anticoagulation for any reasons.
- Previous treatment (within the last 4 weeks) with: i) oral corticosteroid greater than prednisolone equivalent of 10mg/day; or ii) parenteral/intra-articular corticosteroid injection.
- Previous treatment (within the last 12 weeks) with: i) other DMARDs such as sulfasalazine,hydroxychloroquine,chloroquine,gold salts, etc; or ii) investigational drug(s); or iii) other immunosuppressive agents such as cyclophosphamide,cyclosporin,azathioprine and any biologic agents, e.g. anti-TNF.
- Previous treatment(any duration) with i) Leflunomide; or ii) Sulfasalazine used together with methotrexate
- Contraindication to MRI (e.g. pacemakers, metallic implants/stents, claustrophobia).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Methotrexate plus sulfasalazine
ARM 1(Methotrexate(MTX) plus Sulfasalazine(SSZ)) SSZ:Oral form, 2g/day, with escalation regime starting from 1g/day for the first week and increase to 1.5g/day in the next week and increasing to 2g/day by the third week. Total treatment period is 16 weeks. After reaching 2g/day, if patients conditions warrants (and no contraindication), SSZ may be increased at 0.5g per clinic visit) up to a maximum of 3g/day. MTX:Kept at the highest optimal dose. |
ARM 1(Methotrexate(MTX) plus Sulfasalazine(SSZ)) SSZ:Oral form, 2g/day, with escalation regime starting from 1g/day for the first week and increase to 1.5g/day in the next week and increasing to 2g/day by the third week. Total treatment period is 16 weeks. After reaching 2g/day, if patients conditions warrants (and no contraindication), SSZ may be increased at 0.5g per clinic visit) up to a maximum of 3g/day. MTX:Kept at the highest optimal dose. |
ACTIVE_COMPARATOR: Leflunomide
ARM 2:Leflunomide(LEF) LEF: Oral form, 20mg every other day for first 2 weeks then increasing to 20mg per day by the third week. Total treatment period is 16 weeks. Methotrexate:Off |
ARM 2:Leflunomide(LEF) LEF: Oral form, 20mg every other day for first 2 weeks then increasing to 20mg per day by the third week. Total treatment period is 16 weeks. Methotrexate:Off |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
MRI synovitis score
Time Frame: four months
|
four months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MRI bone marrow edema score
Time Frame: 4 months
|
4 months
|
|
MRI erosion score
Time Frame: 4 months
|
4 months
|
|
US synovitis score
Time Frame: 4 months
|
4 months
|
|
clinical outcomes
Time Frame: 4 months
|
Swollen/Tender joint counts, investigator's global assessment of disease activity (0-10), patient's assessment of disease activity (0-10), pain assessment by visual analogue scale (0-10), erythrocyte sedimentation rate, duration (mins) of early morning stiffness, and calculated disease activity indices
|
4 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
US erosion score
Time Frame: 4 months
|
4 months
|
US tenosynovitis score
Time Frame: 4 months
|
4 months
|
MRI tenosynovitis score
Time Frame: 4 months
|
4 months
|
Adverse events
Time Frame: 4 months
|
4 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: York Kiat Tan, MBBS,MRCP, Singapore General Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Arthritis, Rheumatoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gastrointestinal Agents
- Dermatologic Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Methotrexate
- Leflunomide
- Sulfasalazine
Other Study ID Numbers
- YK 01-2012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
Clinical Trials on Methotrexate plus sulfasalazine
-
Karolinska InstitutetCompleted
-
PfizerCompletedRheumatoid ArthritisUnited States, Mexico, Argentina, Chile, Croatia, Czech Republic, Hungary, Poland, Puerto Rico
-
University of NebraskaCompletedRheumatoid ArthritisUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedRheumatoid ArthritisHong Kong, Philippines, Taiwan, Thailand, India, Korea, Republic of, Malaysia, Singapore
-
University Hospital, Strasbourg, FranceRecruitingRheumatoid Arthritis | Insufficient Response to Methotrexate or LeflunomideFrance
-
Helsinki University Central HospitalFoundation for Paediatric Research, Finland; Päivikki and Sakari Sohlberg Foundation... and other collaboratorsCompletedJuvenile Idiopathic ArthritisFinland
-
Nanfang Hospital of Southern Medical UniversityCompletedAnkylosing SpondylitisChina
-
SanofiRegeneron PharmaceuticalsCompletedRheumatoid ArthritisHungary, Portugal, Austria, United States, Argentina, Australia, Brazil, Canada, Czechia, Germany, Greece, Guatemala, Israel, Italy, Korea, Republic of, Lithuania, Mexico, New Zealand, Peru, Poland, Romania, Russian Federation, Spain, Taiwa... and more
-
University of Alabama at BirminghamPfizer; Amgen; Barr LaboratoriesCompleted
-
Tongji HospitalGeneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)RecruitingCholangiocarcinoma Non-resectableChina